Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 102598, 10 pages
http://dx.doi.org/10.1155/2014/102598
Research Article

Performance and Logistical Challenges of Alternative HIV-1 Virological Monitoring Options in a Clinical Setting of Harare, Zimbabwe

1Amsterdam Institute for Global Health and Development (AIGHD), Department of Global Health, Academic Medical Center, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands
2Newlands Clinic, 56 Enterprise Road, Newlands, Harare, Zimbabwe
3Department of Molecular Medicine and Haematology, University of the Witwatersrand 7 York Road, Parktown, Johannesburg 2193, South Africa

Received 31 January 2014; Revised 25 April 2014; Accepted 18 May 2014; Published 15 June 2014

Academic Editor: Antonio Pacheco

Copyright © 2014 Pascale Ondoa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. WHO, Global Update on HIV Treatment 2013: Results, Impact and Opportunities, World Health Organization, Geneva, Switzerland, 2013.
  2. United Nations General Assembly. Political declaration on HIV/AIDS: intensifying our efforts to eliminate HIV/AIDS—United Nations General Assembly Resolution 65/277, New York, NY, USA, United Nations, 2011.
  3. WHO, Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. RecommendAtions for a Public Health Approach.
  4. WHO, The Strategic Use of Antiretrovirals to Help End the HIV Epidemic, World Health Organization, Geneva, Switzerland, 2012, http://apps.who.int/iris/bitstream/10665/75184/1/9789241503921_eng.pdf.
  5. K. C. E. Sigaloff, R. L. Hamers, C. L. Wallis et al., “Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa,” Journal of Acquired Immune Deficiency Syndromes, vol. 58, no. 1, pp. 23–31, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. K. C. E. Sigaloff, T. Ramatsebe, R. Viana, T. F. R. de Wit, C. L. Wallis, and W. S. Stevens, “Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa,” AIDS Research and Human Retroviruses, vol. 28, no. 2, pp. 171–175, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. R. H. Haubrich, J. S. Currier, D. N. Forthal et al., “A randomized study of the utility of human immunodefidency virus RNA measurement for the management of antiretroviral therapy,” Clinical Infectious Diseases, vol. 33, no. 7, pp. 1060–1068, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Furrer, “Is it safe to discontinue primary pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed hiv infection and a CD4 cell count <200 cells/μL,” Clinical Infectious Diseases, vol. 51, no. 5, pp. 611–619, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. H. B. Gale, S. R. Gitterman, H. J. Hoffman et al., “Is frequent CD4+ T-lymphocyte count monitoring necessary for persons with counts ≥300 cells/μL and HIV-1 suppression?” Clinical Infectious Diseases, vol. 56, no. 9, pp. 1340–1343, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. M. R. Loutfy, W. Wu, M. Letchumanan et al., “Systematic review of HIV transmission between heterosexual serodiscordant couples where the HIV-positive partner is fully suppressed on antiretroviral therapy,” PLoS ONE, vol. 8, no. 2, Article ID e55747, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. D. V. Havlir, R. Bassett, D. Levitan et al., “Prevalence and predictive value of intermittent viremia with combination HIV therapy,” Journal of the American Medical Association, vol. 286, no. 2, pp. 171–179, 2001. View at Google Scholar · View at Scopus
  12. W. S. Stevens, L. E. Scott, and S. M. Crowe, “Quantifying HIV for monitoring antiretroviral therapy in resource-poor settings,” The Journal of infectious diseases, vol. 201, pp. S16–S26, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. L. M. Coetzee, S. S. Tay, D. Lawrie, G. Janossy, and D. K. Glencross, “From research tool to routine test: CD38 monitoring in HIV patients,” Cytometry B—Clinical Cytometry, vol. 76, no. 6, pp. 375–384, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. D. K. Glencross, G. Janossy, L. M. Coetzee et al., “CD8/CD38 activation yields important clinical information of effective antiretroviral therapy: Findings from the first year of the CIPRA-SA cohort,” Cytometry B—Clinical Cytometry, vol. 74, supplement 1, pp. S131–S140, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Schüpbach, “Measurement of HIV-1 p24 antigen by signal-amplification-boosted ELISA of heat-denatured plasma is a simple and inexpensive alternative to tests for viral RNA,” AIDS Reviews, vol. 4, no. 2, pp. 83–92, 2002. View at Google Scholar · View at Scopus
  16. S. A. Fiscus, “HIV-1 viral load assays for resource-limited settings: Authors' reply [5],” PLoS Medicine, vol. 3, no. 12, p. 2461, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. V. L. Greengrass, S. P. Turnbull, J. Hocking et al., “Evaluation of a low cost reverse transcriptase assay for plasma HIV-1 viral load monitoring,” Current HIV Research, vol. 3, no. 2, pp. 183–190, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Seyoum, D. Wolday, M. Girma et al., “Reverse transcriptase activity for quantitation of HIV-1 subtype C in plasma: relation to RNA copy number and CD4 T-cell count,” Journal of Medical Virology, vol. 78, no. 2, pp. 161–168, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. V. L. Greengrass, M. M. Plate, P. M. Steele et al., “Evaluation of the cavidi exaVir load assay (version 3) for plasma human immunodeficiency virus type 1 load monitoring,” Journal of Clinical Microbiology, vol. 47, no. 9, pp. 3011–3013, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Rouet, D. K. Ekouevi, M. L. Chaix et al., “Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting,” Journal of Clinical Microbiology, vol. 43, no. 6, pp. 2709–2717, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. F. Rouet, M. L. Chaix, E. Nerrienet et al., “Impact of HIV-1 genetic diversity on plasma HIV-1 RNA quantification: Usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test,” Journal of Acquired Immune Deficiency Syndromes, vol. 45, no. 4, pp. 380–388, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Rouet, V. Foulongne, J. Viljoen et al., “Comparison of the Generic HIV Viral Load assay with the Amplicor HIV-1 Monitor v1.5 and Nuclisens HIV-1 EasyQ v1.2 techniques for plasma HIV-1 RNA quantitation of non-B subtypes: The Kesho Bora preparatory study,” Journal of Virological Methods, vol. 163, no. 2, pp. 253–257, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Bronze, S. Aitken, C. Wallis et al., “Evaluation of an affordable HIV-1 virological failure assay and antiretroviral drug resistance genotyping protocol,” Journal of Virological Methods, vol. 194, pp. 300–307, 2013. View at Google Scholar
  24. S. C. Aitken, A. Kliphuis, M. Bronze et al., “Development and evaluation of an affordable real-time qualitative assay for determining HIV-1 virological failure in plasma and dried blood spots,” Journal of Clinical Microbiology, vol. 51, no. 6, pp. 1899–1905, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Schüpbach, Z. Tomasik, M. Knuchel et al., “Optimized virus disruption improves detection of HIV-1 p24 in particles and uncovers a p24 reactivity in patients with undetectable HIV-1 RNA under long-term HAART,” Journal of Medical Virology, vol. 78, no. 8, pp. 1003–1010, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. R. L. Hamers, R. Oyomopito, C. Kityo et al., “Cohort profile: the PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance-HIV drug resistance in sub-Saharan Africa and the Asia-Pacific,” International Journal of Epidemiology, vol. 41, no. 1, Article ID dyq192, pp. 43–54, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. The AIDS and TB unit, Ministry of Health and Children Welfare. Guidelines for antiretroviral therapy in Zimbabwe. National Drug and Therapeutic Policy Advisory Committee (NDTPAC), 2010.
  28. R. L. Hamers, E. Straatsma, C. Kityo et al., “Building capacity for the assessment of HIV drug resistance: experiences from the pharmaccess African studies to evaluate resistance network,” Clinical Infectious Diseases, vol. 54, no. 4, pp. S261–S265, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. R. L. Hamers, P. W. Smit, W. Stevens, R. Schuurman, and T. F. Rinke de Wit, “Dried fluid spots for HIV type-1 viral load and resistance genotyping: a systematic review,” Antiviral Therapy, vol. 14, no. 5, pp. 619–629, 2009. View at Google Scholar · View at Scopus
  30. R. Dachraoui, A. Depatureaux, M. Chakroun et al., “Monitoring of HIV-1 resistance in Tunisia (North Africa) with a dried plasma spot strategy,” Journal of Acquired Immune Deficiency Syndromes, vol. 47, no. 4, pp. 522–525, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. B. Amellal, C. Katlama, and V. Calvez, “Evaluation of the use of dried spots and of different storage conditions of plasma for HIV-1 RNA quantification,” HIV Medicine, vol. 8, no. 6, pp. 396–400, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. J. G. Prado, A. Shintani, M. Bofill, B. Clotet, L. Ruiz, and J. Martinez-Picado, “Lack of longitudinal intrapatient correlation between p24 antigenemia and levels of HIV-1 RNA in patients with chronic HIV infection during structured treatment interruptions,” Journal of Clinical Microbiology, vol. 42, no. 4, pp. 1620–1625, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. D. Bonard, F. Rouet, T. A. Toni et al., “Field Evaluation of an Improved Assay Using a Heat-Dissociated p24 Antigen for Adults Mainly Infected With HIV-1 CRF02_AG Strains in Côte d'Ivoire, West Africa,” Journal of Acquired Immune Deficiency Syndromes, vol. 34, no. 3, pp. 267–273, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. A. S. Perelson, A. U. Neumann, M. Markowitz, J. M. Leonard, and D. D. Ho, “HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time,” Science, vol. 271, no. 5255, pp. 1582–1586, 1996. View at Google Scholar · View at Scopus
  35. F. Rouet and C. Rouzioux, “The measurement of HIV-1 viral load in resource-limited settings: How and where?” Clinical Laboratory, vol. 53, no. 3-4, pp. 135–148, 2007. View at Google Scholar · View at Scopus
  36. C. Erikstrup, P. Kallestrup, R. B. L. Zinyama-Gutsire et al., “P24 as a predictor of mortality in a cohort of HIV-1-infected adults in Rural Africa,” Journal of Acquired Immune Deficiency Syndromes, vol. 48, no. 3, pp. 345–349, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. M. W. G. Brinkhof, J. Böni, F. Steiner, Z. Tomasik, D. Nadal, and J. Schüpbach, “Evaluation of p24-based antiretroviral treatment monitoring in pediatric HIV-1 infection: prediction of the CD4+ T-cell changes between consecutive visits,” Journal of Acquired Immune Deficiency Syndromes, vol. 41, no. 5, pp. 557–562, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. 2014, http://apps.who.int/medicinedocs/fr/d/Js4889f/12.html.
  39. R. L. Hamers, C. L. Wallis, C. Kityo et al., “HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study,” The Lancet Infectious Diseases, vol. 11, no. 10, pp. 750–759, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. D. E. Bennett, S. Bertagnolio, D. Sutherland, and C. F. Gilks, “The World Health Organization's global strategy for prevention and assessment of HIV drug resistance,” Antiviral Therapy, vol. 13, supplement 2, pp. 1–13, 2008. View at Google Scholar · View at Scopus
  41. WHO, HIV Drug Resistance Report 2012, World Health Organization, Geneva, Switzerland, 2012.
  42. R. L. Hamers, A. W. Sawyer, M. Tuohy, W. S. Stevens, T. F. R. de Wit, and A. M. Hill, “Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis,” AIDS, vol. 26, no. 13, pp. 1663–1672, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. F. K. Sawe and J. A. Mclntyre, “Monitoring HIV antiretroviral therapy in resource-limited settings: time to avoid costly outcomes,” Clinical Infectious Diseases, vol. 49, no. 3, pp. 463–465, 2009. View at Publisher · View at Google Scholar · View at Scopus